Golden
Zogenix

Zogenix

A company focused on development of products to treat central nervous system disorders, pain and rare diseases

Zogenix develops and commercializes central nervous system (CNS) therapies that address specific clinical needs for people with orphan and other CNS disorders. Zogenix’s primary focus is epilepsy and related seizures disorders.

Pipeline



Zogenix announced in 2019 its intention to resubmit its New Drug Application for FINTEPLA (ZX008, fenfluramine) with agreement from the FDA, later that year for treatment of seizures associated with Dravet syndrome. Issues in a previous FDA Refusal to File letter were addressed. The FDA has separately rescinded FINTEPLA for treatment of seizures associated with Dravet syndrome due to it no longer meeting administrative criteria for designation as there are two approved therapies for the disease. In clinical trials, comparisons were not made with the recently approved cannabidiol since it was an investigational product at the time. FINTEPLA has been accepted for review by the European Medicines Agency and is in development in Japan. The drug is being evaluated in a multi-national Phase 3 clinical trial for treatment of seizures associated with Lennox-Gastaut Syndrome. Fenfluramine is an amphetamine derivative and was originally approved as an appetite suppressant and stimulates release of serotonin from vesicular storage and modulated serotonin transporter function.



Relday (risperidone once-monthly long-acting injectable) is a product candidate for the treatment of schizophrenia. Rishperidone is used to treat symptoms of schizophrenia and bipolar disorder in adults and teenagers. Relday is a long-acting injectable form of risperidone and it has completed Phase I clinical studies as of 2019.

Timeline

October 28, 2016

Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients

Funding rounds

2 Results
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Arun Mistry

Employee



Ashish Sagrolikar

Executive Vice President and Chief Commercial Officer



Bradley S. Galer, M.D.

Executive Vice President and Chief Medical Officer



Charles Herst

Employee



Gail M. Farfel, Ph.D.

Executive Vice President and Chief Development Officer



Karen Olson

Employee



Michael P. Smith

Executive Vice President, Chief Financial Officer, Treasurer and Secretary



Sophia Xue

Employee



Stephen J. Farr, Ph.D.

President, CEO



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References